These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 23076661)

  • 1. Atorvastatin-related rhabdomyolysis and acute renal failure in a genetically predisposed patient with potential drug-drug interaction.
    Marusic S; Lisicic A; Horvatic I; Bacic-Vrca V; Bozina N
    Int J Clin Pharm; 2012 Dec; 34(6):825-7. PubMed ID: 23076661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Genetic marker of statin-induced rhabdomyolysis].
    Chiba K; Morimoto K
    Yakugaku Zasshi; 2011 Feb; 131(2):247-53. PubMed ID: 21297370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statin-associated acute interstitial nephritis and rhabdomyolysis.
    Panchangam V
    Saudi J Kidney Dis Transpl; 2014 May; 25(3):659-60. PubMed ID: 24821172
    [No Abstract]   [Full Text] [Related]  

  • 4. Rhabdomyolysis with acute renal failure probably related to the interaction of atorvastatin and delavirdine.
    Castro JG; Gutierrez L
    Am J Med; 2002 Apr; 112(6):505. PubMed ID: 11959068
    [No Abstract]   [Full Text] [Related]  

  • 5. Re: Efflux transporter-mediated interactions with atorvastatin--interesting findings with multiple substrates: istradefylline, verapamil, and rifampicin.
    Rao N
    J Clin Pharmacol; 2011 May; 51(5):784. PubMed ID: 20671297
    [No Abstract]   [Full Text] [Related]  

  • 6. Rhabdomyolysis with concurrent atorvastatin and diltiazem.
    Lewin JJ; Nappi JM; Taylor MH
    Ann Pharmacother; 2002 Oct; 36(10):1546-9. PubMed ID: 12243603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of OATP1B1, MDR1, and CYP3A4 expression in liver and intestine on interpatient pharmacokinetic variability of atorvastatin in obese subjects.
    Ulvestad M; Skottheim IB; Jakobsen GS; Bremer S; Molden E; Asberg A; Hjelmesæth J; Andersson TB; Sandbu R; Christensen H
    Clin Pharmacol Ther; 2013 Mar; 93(3):275-82. PubMed ID: 23361102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren.
    Vaidyanathan S; Camenisch G; Schuetz H; Reynolds C; Yeh CM; Bizot MN; Dieterich HA; Howard D; Dole WP
    J Clin Pharmacol; 2008 Nov; 48(11):1323-38. PubMed ID: 18784280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine.
    Maltz HC; Balog DL; Cheigh JS
    Ann Pharmacother; 1999 Nov; 33(11):1176-9. PubMed ID: 10573315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atorvastatin-induced early-onset rhabdomyolysis in a patient with nephrotic syndrome.
    Jose J; Saravu K; Shastry BA
    Am J Health Syst Pharm; 2007 Apr; 64(7):726-9. PubMed ID: 17384358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe rhabdomyolysis as a consequence of the interaction of fusidic acid and atorvastatin.
    Magee CN; Medani SA; Leavey SF; Conlon PJ; Clarkson MR
    Am J Kidney Dis; 2010 Nov; 56(5):e11-5. PubMed ID: 20888103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rhabdomyolysis with atorvastatin and fusidic acid.
    O'Mahony C; Campbell VL; Al-Khayatt MS; Brull DJ
    Postgrad Med J; 2008 Jun; 84(992):325-7. PubMed ID: 18644925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atorvastatin metabolite measurements as a diagnostic tool for statin-induced myopathy.
    Skottheim IB; Bogsrud MP; Hermann M; Retterstøl K; Åsberg A
    Mol Diagn Ther; 2011 Aug; 15(4):221-7. PubMed ID: 21815705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus.
    Lemahieu WP; Hermann M; Asberg A; Verbeke K; Holdaas H; Vanrenterghem Y; Maes BD
    Am J Transplant; 2005 Sep; 5(9):2236-43. PubMed ID: 16095503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk management of simvastatin or atorvastatin interactions with CYP3A4 inhibitors.
    Molden E; Skovlund E; Braathen P
    Drug Saf; 2008; 31(7):587-96. PubMed ID: 18558792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug interactions with simvastatin.
    Med Lett Drugs Ther; 2008 Oct; 50(1297):83-4. PubMed ID: 18927522
    [No Abstract]   [Full Text] [Related]  

  • 17. Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy.
    Hermann M; Bogsrud MP; Molden E; Asberg A; Mohebi BU; Ose L; Retterstøl K
    Clin Pharmacol Ther; 2006 Jun; 79(6):532-9. PubMed ID: 16765141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statin-induced rhabdomyolysis and dermatomyositis: a rare combination.
    Cannon CS
    JAAPA; 2012 Aug; 25(8):30, 32-3. PubMed ID: 22928274
    [No Abstract]   [Full Text] [Related]  

  • 19. [Rhabdomyolysis associated with atorvastatin combined with amiodarone and fluconazole].
    Franz CC; Bruggisser M; Krähenbühl S; Rätz Bravo AE
    Praxis (Bern 1994); 2011 Mar; 100(5):273-84. PubMed ID: 21365557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efflux transporter-mediated interactions with atorvastatin--interesting findings with multiple substrates: istradefylline, verapamil, and rifampicin.
    Srinivas NR
    J Clin Pharmacol; 2009 Dec; 49(12):1492-3. PubMed ID: 19955497
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.